Abstract
Ifosfamide is an analogue of cyclophosphamide active in the treatment of numerous tumours. Although its use by continuous infusion seems to be responsible for less toxicity, differences of efficacy and toxicity, observed according to its doses and schedules of administration, still remain debated. The objective of this study was to assess the toxicity of high-dose ifosfamide given by continuous infusion over 6 days and its therapeutic activity in various advanced tumours. Twenty-six patients were treated with 14 g/m2 ifosfamide, an equal dose of MESNA, and routine granulocyte- or granulocyte/macrophage-colony-stimulating factor during the intercycle. Courses were repeated every 3 weeks until disease progression or unacceptable toxicity occurred; 75 cycles were administered. The mean number of cycles per patient was 3 (range 1–11). Extrahaematological toxicity was manageable in most patients, WHO grade II or more neurological (5 patients) and renal (5 patients) toxicities occurring in those heavily pretreated with platinum compounds and presenting peritoneal disease. WHO grade III or more neutropenia occurred in 60% of cycles, while grade III–IV thrombocytopenia and anaemia were observed in 19% of them. Three partial responses (germ-cell tumour, chondrosarcoma, soft-tissue sarcoma) and one complete response (metastatic osteosarcoma) were assessed, all in patients with tumours refractory or resistant to standard-dose ifosfamide, which underlines the possibility of circumventing the resistance to ifosfamide given in conventional schedules. The present results confirm previous reports of changes in the therapeutic index of ifosfamide according to its dose and administration schedule.
Similar content being viewed by others
References
Allen LM, Creaven PJ (1972) Effect of microsomal activation on interaction between ifosfamide and DNA. J Pharm Sci 61:2009–2011
Antman KH, Ryan L, Elias A, Sherman D, Grier HE (1989) Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma. J Clin Oncol 7:126–131
Boddy AV, Yule SM, Wyllie R, Price L, Pearson ADJ, Idle JR (1995) Comparison of continuous infusion and bolus administration of ifosfamide in children. Eur J Cancer 31A:785–790
Bramwell VHC, Mouridsen HT, Santoro A, Blackledge G, Somers J, Verwey J, Dombernowsky P, Onsrud M, Thomas D, Sylvester R, Van Oosterom A (1987) Cyclophosphamide versus ifosfamide: final report of a randomized phase II trial in adult soft tissue sarcomas. Eur J Cancer Clin Oncol 23:311–321
Cabanillas F, Hagemeister FB, Bodey GP, Freireich EJ (1982) IMVP-16: an effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy. Blood 60:693–697
Cerny T, Castiglione M, Brunner K, Küpfer A, Martinelli G, Lind M (1990) Ifosfamide by continuous infusion to prevent encephalopathy. Lancet 1:175
Chang TKH, Weber GF, Crespi CL, Waxman DJ (1993) Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res 53:5629–5637
Earl HM (1987) Chemotherapy of rare malignant bone tumours. Baillère's Clin Oncol 1:223–241
Elias AD, Eder JP, Shea T, Begg CB, Frei III E, Antman KH (1990) High-dose ifosfamide with mesna uroprotection: a phase I study. J Clin Oncol 8:170–178
Goldin A (1982) Ifosfamide in experimental tumor systems. Semin Oncol 9:14–23
Hoefer-Janker H, Scheef W, Gunther W, Hüls W (1975) Erfahrungen mit der fracktionierten ifosfamide-stobtherapie bei generalisierten malignen tumoren. Med Welt 26:972–979
Kamen BA, Frenkel E, Colvin OM (1995) Ifosfamide: should the honeymoon be over? J Clin Oncol 13:307–309
Keizer HJ, Quwerkerk J, Welvaart K, Velde CJH van der, Cleton FJ (1995) Ifosfamide treatment as a 10-day continuous intravenous infusion. J Cancer Res Clin Oncol 121:297–302
Le Cesne A, Antoine E, Spielmann M, Le Chevalier T, Brain E, Toussaint C, Janin N, Kayitalire L, Fontaine F, Genin J, Vanel D, Contesso G, Tursz T (1995) High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas. J Clin Oncol 13:1600–1608
Morgan LR, Harrison EF, Hawke JE, Hunter HL, Costanzi JJ, Plotkin D, Tucker WG, Worrall PM (1982) Toxicity of single vs. fractionated-dose ifosfamide in non-small cell lung cancer: a multi-center study. Semin Oncol 9 [Suppl 1]:66–70
Rosen G, Forscher C, Lowenbraum S, Eilber F, Eckardt J, Holmes C, Fu YS (1994) Synovial sarcoma: uniform response of metastases to high dose ifosfamide. Cancer 73:2506–2511
Rossi R, Gödde A, Kleinebrand A, Riepenhausen M, Boos J, Ritter J, Jürgens H (1994) Unilateral nephrectomy and cisplatin as risk factors of ifosfamide-induced nephrotoxicity: analysis of 120 patients. J Clin Oncol 12:159–165
Sladek NE (1994) Metabolism and pharmacokinetic behavior of cyclophosphamide and related oxazaphosphorines. In: Powis G (ed) Anticancer drugs: reactive metabolism and interactions, Pergamon, Oxford, pp 79–156
Suarez A, McDowell H, Niaudet P, Comoy E, Flamant F (1991) Long-term follow-up of ifosfamide renal toxicity in children treated for malignant mesenchymal tumors: an International Society of Pediatric Oncology report. J Clin Oncol 9:2177–2182
Toma S, Palumbo R, Comandone A, Oliva C, Vincenti M, Bumma C, Rosso R (1995) Ambulatory 4-day continuous-infusion schedule of high-dose ifosfamide with mesna uroprotection and granulocyte colony-stimulating factor in advanced solid tumours: a phase II study. Ann Oncol 6:193–196
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Brain, E.C.G., Mita, A., Soulié, P. et al. 6-day continuous infusion of high-dose ifosfamide with bone marrow growth factors in advanced refractory malignancies. J Cancer Res Clin Oncol 123, 227–231 (1997). https://doi.org/10.1007/BF01240320
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01240320